Meeting
2023 ASCO Annual Meeting
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).
Authors
Oscar Reig Torras
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
Oscar Reig Torras , Marta Garcia de Herreros , Natalia Jiménez , Caterina Aversa , Mercedes Marín-Aguilera , Laura Ferrer Mileo , Leonardo Rodriguez-Carunchio , Isabel Trias , Albert Font Pous , Alejo Rodriguez-Vida , Montserrat Domenech-Santasusana , Mariona Figols , Miguel Ángel Climent , Sara Cros Costa , Isabel Chirivella , Daniel Herrero Rivera , Daniel Jiménez-Peralta , Enrique Gonzalez -Billalabeitia , Joan Carles , Begoña Mellado-Gonzalez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5083)
DOI
10.1200/JCO.2023.41.16_suppl.5083
Abstract #
5083
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Tumor suppressor genes (TSG), treatment, and survival in de novo metastatic hormone-sensitive prostate cancer.
First Author: Martin W. Schoen
Poster
2023 ASCO Annual Meeting
Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.
First Author: Anis Hamid
Poster
2023 ASCO Genitourinary Cancers Symposium
Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
First Author: Can Aydogdu
Poster
2021 ASCO Annual Meeting
Association of androgen receptor signature and RB1, PTEN, TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.
First Author: Laura Ferrer-Mileo